Insulin and Amylin: Restoring Balance in Glycemic Control

Release Date: May 2006
Expiration Date: May 2008

TARGET AUDIENCE
This continuing education activity is designed for certified diabetes educators, nurses, pharmacists, and other healthcare providers who treat patients with type 1 or type 2 diabetes.

STATEMENT OF NEED
Pramlintide, the recently approved analogue of the human hormone amylin, is the first antihyperglycemic agent for type 1 diabetes since the introduction of insulin more than 80 years ago. The users of this activity will learn the importance and benefits of a multihormonal approach to glycemic control, the criteria for patient selection, and how to safely initiate therapy in appropriate patients with type 1 or insulin-requiring type 2 diabetes.

EDUCATIONAL OBJECTIVES
Upon completion of this activity, the participant should be able to:

• Describe glucoregulatory actions performed by the hormone amylin that supplement the actions of insulin.
• Describe differences in the effects caused by the loss of amylin secretion in type 1 and type 2 diabetes.
• Cite safety and efficacy data from clinical trials of the amylin hormone analogue pramlintide that show its effect on patients with type 1 or type 2 diabetes.
• Determine which patients are suitable candidates for pramlintide therapy, proper protocols for initiating therapy in these patients, and safety issues of which both patients and caregiver should be aware.

ACCREDITATION

	Nursing: This program for 1.0 contact hours has been approved by the American Association of Diabetes Educators (AADE), which is accredited as an approver of continuing education in nursing by the American Nurse's Credentialing Center's Commission on Accreditation. Approval of this continuing education activity does not imply endorsement by the AADE. Approval Number 0506-090.
	Dietitian: The American Association of Diabetes Educators is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR) from June 1, 2006 to May 31, 2009. Registered Dietitians (RDs) and Dietetic Technicians, Registered (DTRs) will receive 2.0 continuing professional education units (CPEUs) for completion of this program. CPE Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.
	Pharmacist: The American Association of Diabetes Educators is approved by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program provides 1.25 contact hours (0.125 CEUs) of continuing education credit. ACPE Universal Program Number: 069-999-06-040-H01 Effective date: May 2006 to May 2008

FACULTY INFORMATION
Catherine Martin, MS, APRN, BC-ADM, CDE
Clinical Care Coordinator
University of Michigan Health Systems
Department of Internal Medicine
Division of Metabolism, Endocrinology, and Diabetes
Ann Arbor, Michigan

Steven V. Edelman, MD
Professor of Medicine
University of California San Diego
Veterans Affairs Medical Center
San Diego, California

Susan K. Owen, RN, MSN, CDE
Clinical Nurse Specialist, Diabetes
Grand Rapids Associated Internists
Grand Rapids, Michigan

Laura Laighton Want, RN, MS, CDE, BC-ADM
Clinical Research Study Coordinator
Diabetes Nurse Educator
MedStar Clinical Research Center
Washington, DC

FACULTY DISCLOSURES
It is the policy of the American Association of Diabetes Educators to require faculty for all educational programs to complete the Financial Relationships & Conflict of Interest Statement. This information is required in order to be in compliance with the FDA and AADE's credentialing bodies.

In order to clarify and accurately present the relationship of the speaker to industry and other organizations, the speakers of this activity have disclosed the following:

Catherine Martin
has received honoraria related to speaker-bureau activities from Amylin Pharmaceuticals, Inc. and Eli Lilly and Company.

Dr. Steven Edelman
has received honoraria related to formal advisory activities from Eli Lilly and Company; Amylin Pharmaceuticals, Inc.; and Takeda Pharmaceuticals America, Inc. He has received honoraria related to specific research activities from Pfizer, Inc; Eli Lilly and Company; and NovoNordisk Pharmaceuticals, Inc. Dr. Edelman has received honoraria related to the development of educational materials from Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Metrika, Inc. He has received honoraria related to speaker bureau activities from Takeda Pharmaceuticals America, Inc.; Eli Lilly and Comapny; and GlaxoSmithKline.

Susan Owen
has received honoraria related to speaker-bureau activities from Sanofi-Aventis, Novo Nordisk, and Medtronic MiniMed. She has also received grant support related to research activities from Amylin Pharmaceuticals, Inc.

Laura Laighton Want
has received honoraria related to speaker-bureau activities and advisory board activities from Amylin Pharmaceuticals, Inc. She also owns holdings in Amylin Pharmaceuticals, Inc.

DISCLAIMER
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in this material are not representative of the views of the American Association of Diabetes Educators (AADE). Acceptance of advertising is not to be construed as an endorsement of the product by AADE. No endorsement is intended or implied.

INSTRUCTIONS
To receive a Statement of Credit, you must:

Your statement of credit will be issued immediately upon successful completion of the post-test.

SPONSORED BY
American Association of Diabetes Educators (AADE)

COSPONSORED BY
Vox Medica - Institute for Continuing Healthcare Education.

FEE
$25 members; $35 non-members

COMMERCIAL SUPPORT
Supported by an unrestricted educational grant from Amylin Pharmaceuticals, Inc.

SOFTWARE REQUIREMENTS
Adobe Acrobat Reader
Internet Explorer (5.5 or greater) or Firefox
Internet Explorer is not supported on the Macintosh.
Windows 2000 or above